Wire · opportunities
Maviret cured 96% of HCV patients. The real world is more complicated.
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
AbbVie's Maviret achieved a 96% cure rate for acute hepatitis C in clinical trials, with regulatory approvals in the US and EU to treat acute infections. However, real-world challenges remain with high reinfection rates among vulnerable groups, indicating a need for integrated treatment and prevention strategies beyond antiviral therapy alone.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now treat acute hepatitis C patients earlier due to new approvals, but your clinical strategy must include prevention services to address high reinfection risks in vulnerable groups. Delaying treatment because of reinfections misses a critical chance to reduce disease spread and improve patient outcomes.
◆ Coverage
1 source · 28 Aug 2026
◆ Related on Wire
◆ Topics